Can Fite Biopharma Ltd ADR Cash Flow Conversion Efficiency
Can Fite Biopharma Ltd ADR cash flow conversion efficiency. Based on the latest financial reports, Can Fite Biopharma Ltd ADR (CANF) has a cash flow conversion efficiency ratio of -0.568x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.38 Million) by net assets ($4.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Can Fite Biopharma Ltd ADR (2011–2025)
Cash flow conversion efficiency of Can Fite Biopharma Ltd ADR from 2011 to 2025. This chart illustrates how Can Fite Biopharma Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Can Fite Biopharma Ltd ADR share price for real-time trading data and today's change.
Can Fite Biopharma Ltd ADR Cash Flow Conversion Ratio Explained
Can Fite Biopharma Ltd ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Can Fite Biopharma Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Can Fite Biopharma Ltd ADR ranked by their cash flow conversion efficiency. Also see Can Fite Biopharma Ltd ADR stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Noble Financials SA
WAR:IBS
|
0.010x |
|
Nauticus Robotics Inc.
NASDAQ:KITT
|
-1.374x |
|
Moving iMage Technologies Inc
NYSE MKT:MITQ
|
0.523x |
|
Pinewood Technologies Group PLC
LSE:PINE
|
0.106x |
|
Pembangunan Graha Lestari Tbk
JK:PGLI
|
0.016x |
|
Amaze Holdings Inc
NYSE MKT:AMZE
|
1.001x |
|
Great Divide Mining Ltd
AU:GDM
|
-0.092x |
|
Snipp Interactive Inc
V:SPN
|
-0.018x |
Annual Cash Flow Conversion Efficiency for Can Fite Biopharma Ltd ADR (2011–2025)
The table below shows the annual cash flow conversion efficiency of Can Fite Biopharma Ltd ADR from 2011 to 2025. Review Can Fite Biopharma Ltd ADR free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.59 Million | $-9.02 Million | -1.613x | -14.82% |
| 2024-12-31 | $5.44 Million | $-7.64 Million | -1.405x | -3.92% |
| 2023-12-31 | $6.24 Million | $-8.44 Million | -1.352x | +44.03% |
| 2022-12-31 | $4.47 Million | $-10.80 Million | -2.415x | -252.36% |
| 2021-12-31 | $14.38 Million | $-9.86 Million | -0.685x | +65.49% |
| 2020-12-31 | $6.07 Million | $-12.06 Million | -1.986x | +55.24% |
| 2019-12-31 | $2.44 Million | $-10.83 Million | -4.437x | -221.93% |
| 2018-12-31 | $3.02 Million | $-4.16 Million | -1.378x | +55.81% |
| 2017-12-31 | $3.05 Million | $-9.52 Million | -3.118x | -35.33% |
| 2016-12-31 | $3.87 Million | $-8.93 Million | -2.304x | -417.41% |
| 2015-12-31 | $10.44 Million | $-4.65 Million | -0.445x | +58.32% |
| 2014-12-31 | $6.86 Million | $-7.33 Million | -1.069x | +44.80% |
| 2013-12-31 | $4.46 Million | $-8.63 Million | -1.936x | -131.52% |
| 2012-12-31 | $-707.99K | $-4.35 Million | 6.141x | +467.80% |
| 2011-12-31 | $3.29 Million | $-5.50 Million | -1.670x | -- |
About Can Fite Biopharma Ltd ADR
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase … Read more